First-of-its-Kind custom cancer vaccine tested in patients
NCT ID NCT01970358
Summary
This early-stage study tested a new, personalized vaccine for melanoma, a serious skin cancer. The vaccine was custom-made for each of the 15 participants using the unique genetic features of their own tumor. The main goals were to see if creating and giving this vaccine was safe and possible, and to check if it triggered an immune response that could help prevent the cancer from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.